Skip to content

Kapil Dhingra

Kapil Dhingra joined Servier’s Supervisory Board in March 2022.

Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care and drug development.

Kapil Dhingra is currently a professional Board member.

He served as vice president, head of the oncology disease biology leadership team and head of oncology clinical development at Roche, during which he led numerous drug approvals, including Herceptin®, Tarceva® and Avastin®. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly. Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine and Memorial Sloan Kettering Cancer Center.

Dr. Dhingra is currently chair of the LAVA Therapeutics and also a member of the boards of Black Diamond Therapeutics, Replimune, Median Technologies, Mariana Oncology as well as Kirilys Therapeutics.

Dr. Dhingra obtained his bachelor of medicine-bachelor of surgery degree (M.B.B.S.) from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine in Atlanta.